Kevin Bitterman
CIK 1591747 · last filed 2026-09-15
Kevin Bitterman is a corporate insider who has filed 45 SEC Form 4 insider transactions across 4 companies since 2014. The most recent filing, for IRON, was dated Sep 15, 2026. Across all open-market trades the lifetime net is −$78.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $33.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
IRON price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1000 WINTER STREET, SUITE 3350
WALTHAM, MA 02451
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IRON | Director | 336,002 | $78.93 | $26.52M | -$53.63M | 23 | 2026-09-15 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | $3.48M | 6 | 2021-06-03 |
| EDIT | Director | 2,797,144 | $2.42 | $6.77M | -$31.19M | 10 | 2017-06-19 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 171,820 | $0.00 | $103 | $2.79M | 3 | 2016-06-07 |
Recent Filings
45 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-15 | IRON | Mixed | — | -$679.4K | EDGAR |
| 2026-09-11 | IRON | Notice (144) | −27,136 | -$1.90M | EDGAR |
| 2026-09-09 | IRON | Sell (S) | −1,689 | -$135.1K | EDGAR |
| 2026-09-03 | IRON | Sell (S) | −54,496 | -$4.37M | EDGAR |
| 2026-06-23 | IRON | Grant (A) | — | $0 | EDGAR |
| 2025-12-18 | IRON | Sell (S) | −754 | -$69.0K | EDGAR |
| 2025-12-16 | IRON | Mixed | −177,123 | -$16.76M | EDGAR |
| 2025-12-15 | IRON | Notice (144) | −7,000 | -$643.1K | EDGAR |
| 2025-10-17 | IRON | Sell (S) | −93,585 | -$8.05M | EDGAR |
| 2025-10-09 | IRON | Sell (S) | −90,000 | -$6.31M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.